[{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"PARP","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research \/ IDEAYA Biosciences "},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"TGL-100","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Research \/ Touchlight"},{"orgOrder":0,"company":"Cancer Research","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"Fc?RllB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Teon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Aleta Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research Technology Ltd.","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research Technology Ltd."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"HTL0039732","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cancer Research \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Research \/ Cancer Research"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cancer Research \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ Cancer Research"}]

Find Clinical Drug Pipeline Developments & Deals by Cancer Research

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.

                          Brand Name : HTL0039732

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 10, 2023

                          Lead Product(s) : HTL0039732,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Sosei Heptares

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.

                          Brand Name : AST-VAC2

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          July 24, 2023

                          Lead Product(s) : AST-VAC2

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Lineage Cell Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.

                          Brand Name : HTL0039732

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 22, 2022

                          Lead Product(s) : HTL0039732

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Sosei Group Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Following the option exercise, IDEAYA holds exclusive worldwide license rights covering a broad class of PARG inhibitors. IDEAYA owns all commercial rights in IDE161, subject to economic obligations, worldwide license with Cancer Research UK and Universi...

                          Brand Name : IDE161

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 31, 2022

                          Lead Product(s) : IDE161

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Ideaya Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in ...

                          Brand Name : ALETA-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 23, 2021

                          Lead Product(s) : ALETA-001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Aleta Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The partnership focuses on Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist TT-702, for the treatment of multiplecancers including prostate and triple-negative breast.

                          Brand Name : TT-702

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 01, 2021

                          Lead Product(s) : TT-702

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Teon Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : BioInvent is conducting a Phase I/II trial of BI-1206 in combination with rituximab to treat NHL. CRUK decided to end the trial being conducted in the UK after the single-agent part of the study. Both parties have agreed to restructure their agreement co...

                          Brand Name : BI-1206

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 11, 2021

                          Lead Product(s) : BI-1206,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : BioInvent

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

                          Brand Name : TGL-100

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 29, 2020

                          Lead Product(s) : TGL-100

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Touchlight

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 11, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Ideaya Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank